Quantum BioPharma
- Country
- Ownership
- -
- Employees
- 8
- Market Cap
- -
- Introduction
Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company's three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property. The company was founded by Thomas Fairfull, Zeeshan Saeed and Anthony J. Durkacz on October 20, 1994 and is headquartered in Toronto, Canada.
Dosing begins in early clinical trial of Lucid-MS to protect myelin sheath
Healthy adults have been dosed in a Phase 1 trial of Lucid-21-302, a potential myelin-protective oral treatment for multiple sclerosis. The trial aims to assess safety and tolerability, with findings expected to inform a Phase 2 trial on efficacy in MS patients. Lucid-MS is designed to protect and possibly repair myelin sheath damage without affecting the immune system.
© Copyright 2025. All Rights Reserved by MedPath